Cerevance Reports Phase 2 Results for Solengepras in Early-Stage Parkinson’s Disease

​Cerevance, a clinical-stage biopharmaceutical company, has announced topline results from its Phase 2 ASCEND trial evaluating solengepras as a monotherapy for early-stage Parkinson's disease. The findings were presented at the AD/PD™ 2025 International Conference in Vienna.​

Solengepras is an oral, non-dopaminergic therapy designed to modulate brain circuits responsible for motor and non-motor functions without directly affecting dopaminergic pathways. This approach aims to reduce motor complications such as dyskinesia and minimize "OFF" periods.​

In the ASCEND trial, solengepras demonstrated a small, non-statistically significant improvement in motor symptoms from baseline to week 12 compared to placebo, as measured by the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II and III. While the primary endpoint was not met, trends toward improvement were observed in several patient-reported measures, including:​

• MDS-UPDRS Part I (-1.38, p=0.12)​

• MDS-UPDRS Part II (-0.4, p=0.62)​

• Non-Motor Symptoms Scale (-1.7, p=0.59)​

• Epworth Sleepiness Scale (-0.3, p=0.62)

These results suggest potential benefits in functional and non-motor aspects of Parkinson's disease.​

Solengepras was generally well tolerated, with all patients in the treatment arm completing the 12-week trial and no discontinuations due to treatment-related adverse events. No serious adverse events related to solengepras were reported, and most were mild and transient. Notably, fewer non-motor symptom-related adverse events occurred in the treatment arm compared to placebo.

Dr. Aaron L. Ellenbogen, primary investigator of the ASCEND trial, emphasized the need for therapies addressing both motor and non-motor symptoms in Parkinson's disease. He noted that solengepras' novel mechanism offers promise in this area.​

Cerevance is continuing its pivotal Phase 3 ARISE trial to evaluate solengepras as an adjunctive therapy in Parkinson's disease, with topline data expected in the first half of 2026.​